Trevor Allred
Stock Analyst at Oppenheimer
(4.88)
# 295
Out of 5,043 analysts
42
Total ratings
83.9%
Success rate
81.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trevor Allred
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Reiterated: Buy | $210 | $138.77 | +51.33% | 9 | Aug 5, 2026 | |
| BBIO BridgeBio Pharma | Rated: Hold | n/a | $65.35 | - | 10 | May 11, 2026 | |
| DNTH Dianthus Therapeutics | Rated: Hold | n/a | $82.37 | - | 7 | May 11, 2026 | |
| INVA Innoviva | Downgraded: Buy | $35 | $21.21 | +65.02% | 3 | Feb 26, 2026 | |
| LGND Ligand Pharmaceuticals | Reiterated: Buy | $250 → $275 | $301.81 | -8.88% | 9 | Nov 7, 2025 | |
| MBX MBX Biosciences | Reiterated: Buy | $38 → $80 | $53.24 | +50.26% | 4 | Nov 7, 2025 |
Palvella Therapeutics
Aug 5, 2026
Reiterated: Buy
Price Target: $210
Current: $138.77
Upside: +51.33%
BridgeBio Pharma
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $65.35
Upside: -
Dianthus Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $82.37
Upside: -
Innoviva
Feb 26, 2026
Downgraded: Buy
Price Target: $35
Current: $21.21
Upside: +65.02%
Ligand Pharmaceuticals
Nov 7, 2025
Reiterated: Buy
Price Target: $250 → $275
Current: $301.81
Upside: -8.88%
MBX Biosciences
Nov 7, 2025
Reiterated: Buy
Price Target: $38 → $80
Current: $53.24
Upside: +50.26%